Pharming Group NV (PHAR)
12.59
0.00 (0.00%)
USD |
NASDAQ |
Jun 10, 16:00
12.59
0.00 (0.00%)
After-Hours: 18:27
Pharming Group Enterprise Value : 828.37M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 828.37M |
| June 08, 2026 | 843.10M |
| June 05, 2026 | 824.95M |
| June 04, 2026 | 819.96M |
| June 03, 2026 | 803.82M |
| June 02, 2026 | 806.63M |
| June 01, 2026 | 864.14M |
| May 29, 2026 | 856.43M |
| May 28, 2026 | 903.42M |
| May 27, 2026 | 864.09M |
| May 26, 2026 | 878.48M |
| May 22, 2026 | 808.59M |
| May 21, 2026 | 822.98M |
| May 20, 2026 | 827.09M |
| May 19, 2026 | 808.59M |
| May 18, 2026 | 809.96M |
| May 15, 2026 | 830.52M |
| May 14, 2026 | 833.26M |
| May 13, 2026 | 833.94M |
| May 12, 2026 | 842.16M |
| May 11, 2026 | 810.21M |
| May 08, 2026 | 834.63M |
| May 07, 2026 | 767.48M |
| May 06, 2026 | 1.069B |
| May 05, 2026 | 1.053B |
| Date | Value |
|---|---|
| May 04, 2026 | 1.068B |
| May 01, 2026 | 1.109B |
| April 30, 2026 | 1.078B |
| April 29, 2026 | 1.066B |
| April 28, 2026 | 1.070B |
| April 27, 2026 | 1.105B |
| April 24, 2026 | 1.088B |
| April 23, 2026 | 1.085B |
| April 22, 2026 | 1.116B |
| April 21, 2026 | 1.119B |
| April 20, 2026 | 1.149B |
| April 17, 2026 | 1.133B |
| April 16, 2026 | 1.133B |
| April 15, 2026 | 1.165B |
| April 14, 2026 | 1.157B |
| April 13, 2026 | 1.107B |
| April 10, 2026 | 1.116B |
| April 09, 2026 | 1.109B |
| April 08, 2026 | 1.109B |
| April 07, 2026 | 1.070B |
| April 06, 2026 | 1.076B |
| April 02, 2026 | 1.084B |
| April 01, 2026 | 1.105B |
| March 31, 2026 | 1.085B |
| March 30, 2026 | 1.033B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 77.22M |
| NewAmsterdam Pharma Co. NV | 2.906B |
| ACADIA Pharmaceuticals, Inc. | 2.936B |
| Alkermes Plc | 8.442B |
| Alnylam Pharmaceuticals, Inc. | 39.69B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.232M |
| Revenue (Quarterly) | 72.71M |
| Total Expenses (Quarterly) | 77.94M |
| EPS Diluted (Quarterly) | -0.0746 |
| Gross Profit Margin (Quarterly) | 90.83% |
| Profit Margin (Quarterly) | -7.20% |
| Earnings Yield | 1.37% |
| Operating Earnings Yield | 3.55% |
| Normalized Earnings Yield | 2.179 |